----

----

----

----

| 1.   | DEFINITIONS |
|----------------|-------------|

| 1.1.   | Definitions. |
|------------------|--------------|

| 1.1.1.   |  “Affiliate”      means, in the case of either Party, any corporation, joint venture, or      other business entity which directly or indirectly controls, is controlled      by, or is under common control with that Party. The term “control,” as      used in this definition, means having the power to direct, or cause the      direction of, the management and policies of an entity, whether through      ownership of voting securities, by contract or otherwise. Notwithstanding      the foregoing, for purposes of this Agreement, the term “Affiliate” does      not include entities in which a Party or its Affiliates owns a majority of      the ordinary voting power to elect a majority of the board of directors      but is restricted from electing such majority by contract or otherwise,      until such time as such restrictions are no longer in    effect. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.2.   | “Batch”      means the volume of finished, packaged Products obtained from a validated      Manufacturing run. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------|

| 1.1.3.   | “Certificate      of Analysis” means the document identifying the results of the Methods of      Analysis for a specific Batch of Product in a form agreed to by the      Parties in writing but which shall include, without limitation, the      applicable Product Batch’s manufacturing date, expiration date, lot number      and testing results and data. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.4.   | “Confidential      Information” means either MEDA Confidential Information, ULURU      Confidential Information, or both, as the context  requires. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.5.   | “Contract      Year” means each consecutive twelve (12) month period during the Term, the      first of which shall commence on the first day of the calendar month      following the date of Launch and end on the first anniversary      thereof. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.6.   | “Control”      means, with respect to any item of information or intellectual property      right, the possession, whether by ownership or exclusive license, of the      right to grant a license or other right with respect    thereto. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.7.   | “Effective      Date” has the meaning set forth in thePreamble. |
|--------------------|-----------------------------------------------------------------------------|

| 1.1.8.   | “EMEA”      means (a) the European Medicines Evaluation Agency, London, United      Kingdom, or (b) any local regulatory agency or governmental entity which      fulfills a role similar to the EMEA, or any successor entities      thereto. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.9.   | “Facility”      and / or “Facilities” means any and all facilities regarding the      Manufacture of the Products and the supply of the Materials, which are      listed in Exhibit B or      any subsequent or replacement facilities approved by  MEDA. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.10.   | “Field”      means the prevention and treatment of aphthous  ulcers. |
|---------------------|----------------------------------------------------------------------------------|

| 1.1.11.   | “Force      Majeure Event” has the meaning set forth in Article  11. |
|---------------------|----------------------------------------------------------------------------------|

| 1.1.12.   | “Good      Manufacturing Practice” or “GMP” means (a) the then current standards for      the manufacture of pharmaceuticals, (b) such standards of good      manufacturing practice as are required by the applicable laws and      regulations of countries in which the Product is intended to be sold, to      the extent such standards are not inconsistent with the then current      standards for the manufacture of pharmaceuticals as set forth in the      FD&C Act, and (c) any quality requirements set forth in this Agreement      or the Quality Agreement attached hereto as Exhibit      C. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.13.   | “Indemnified      Party” has the meaning set forth in Section  8.1.3. |
|---------------------|-----------------------------------------------------------------------------------|

| 1.1.14.   | “Indemnifying      Party” has the meaning set forth in Section  8.1.3. |
|---------------------|------------------------------------------------------------------------------------|

| 1.1.15.   | “Intellectual      Property Rights” means Patents, designs, formulae, trade secrets,      know-how, industrial models, and technical information Controlled by ULURU      and whether now existing or coming into existence during the Term and      which are necessary for and/or related to the use or distribution of the      Products. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.16.   | “Invention”      means any new or useful method, process, manufacture, compound or      composition of matter, whether or not patentable or copyrightable, or any      improvement thereof arising during the Term with respect to the Products,      its Manufacture and/or use. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.17.   | “Launch”      means the date on which the respective Product is sold by MEDA for the      first time to a Third Party for commercial distribution in the      Territory. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.18.   | “Major      Countries” shall mean (i) initially France, Germany, Italy, and United      Kingdom and (ii) potentially later Spain, provided that ULURU had      re-acquired the rights back from Esteve S.A., Spain, in accordance with      Section 3.1.5. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.19.   |  “Manufacture,”      “Manufactured” or “Manufacturing” means all activities involved in the      production of the Products, including, without limitation, the      preparation, formulation, finishing, testing, packaging, storage and      labeling of the Products and the handling, storage and disposal of any      residues or wastes generatedthereby. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.20.   |  “Materials”      means all materials, including, without limitation, all raw materials,      ingredients, packaging supplies and labels, required for the Manufacture      of Products. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.21.   | “MEDA”      has the meaning set forth in thePreamble. |
|---------------------|-------------------------------------------------------------------|

| 1.1.22.   | “MEDA      Confidential Information” means all information, specifications, know-how      and data pertaining to MEDA’s business disclosed to ULURU, its Affiliates      or its Third Party manufacturer hereunder, including, without limitation,      marketing and sales plans, artwork, formats, equipment, logos, drawings,      customer lists, regulatory filings, correspondence with the EMEA or any      other Regulatory Authority, clinical study data, analytical data,      operating procedures and all ordering and sales    information. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.23.   | “MEDA      Trademarks” means any trademarks, trade name, trade dress, slogan, logo,      or similar item selected by MEDA for use in connection with the Products,      including but not limited to the trademark Apthasol®, as listed in Exhibit      J. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.24.   | “Methods      of Analysis” means the methods of analysis for the Products which are      mutually agreed upon in writing between the Parties and, on a date to be      mutually agreed upon by the Parties, attached as an exhibit to this      Agreement. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.25.   | “Net      Sales” means, with respect to the Product, the gross invoiced sales amount      of the Products sold by MEDA or its Affiliates to non-affiliate Third      Parties, after deduction of the following items, to the extent that such      deductions are reasonable and actually allowed, taken or incurred, and      (provided that such items do not exceed reasonable and customary amounts      in the country in which the sale occurred): (a) trade and quantity      discounts, net of any give-backs received by MEDA in return; (b) refunds,      rebates, governmental rebates, retroactive price adjustments, service      allowances and broker’s or agent’s commissions; (c) credits or allowances      given for rejection or return of previously sold Products or for wastage      replacement actually taken or allowed; and (d) any tax, duties or      government charge levied on the sale of Product and borne by MEDA and/or      its Affiliates (excluding national, state or local taxes based on income).      Such amounts shall be determined from the books and records of MEDA and      its Affiliates maintained in accordance with generally accepted accounting      principles, consistently applied. Sales of the Products by and between a      Party and its Affiliates for further distribution to a Third Party are not      sales to Third Parties and shall be excluded from Net Sales calculations      for all purposes. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.26.   | “Old      Agreement” shall have the meaning as set fort in the Preamble of this      Agreement |
|---------------------|------------------------------------------------------------------------------------------------------------|

| 1.1.27.   | “Party”      or “Parties” means either MEDA, ULURU or both, as the context      requires. |
|---------------------|-------------------------------------------------------------------------------------------------------------------|

| 1.1.28.   | “Patents”      shall mean (a) the patents listed in Exhibit D and      (b) any and all patents, patent applications, patent disclosures awaiting      filing determination, patent divisionals, continuations,      continuations-in-part, reissues, re-examinations, renewals and extensions      thereof Controlled by ULURU during the Term, within the Territory, which      are necessary for the Manufacture, use or distribution of the      Products. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.29.   | “Person”      means any natural person, corporation, general partnership, limited      partnership, limited liability company, limited liability partnership      proprietorship, other business organization, trust, union, association or      governmental authority. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.30.   |  “Products”      shall mean the Products listed in Exhibit      A |
|---------------------|------------------------------------------------------------------------------------|

| 1.1.31.   |  “Recall”      means any action by any Party to recover title to or possession of any      Product sold or shipped to Third Parties or any action to prevent or      interrupt the sale or shipment by a Party of the Products to Third Parties      that would have been subject to recall if it had been sold or      shipped. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.32.   | “Regulatory      Approval” means all consents, permits, approvals, licenses,      authorizations, qualifications, notices or orders that are issued or      granted by Regulatory Authorities which are required for the manufacture,      marketing, promotion, pricing and sale of the Products in a country within      the Territory. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.33.   | “Regulatory      Authority” means any domestic or foreign, federal, national, regional,      state, county, city, municipal, local or other administrative, legislative      regulatory or other governmental authority, agency, department, bureau,      commission, or council involved in the granting of Regulatory Approval for      the Products in the Territory. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.34.   | “Rolling      Forecast” has the meaning set forth in Section  3.4. |
|---------------------|--------------------------------------------------------------------------------|

| 1.1.35.   | “Seizure”      means any action by the EMEA or any other Regulatory Authority to detain      or destroy the Products or prevent the release of the      Products. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.36.   | “Specifications”      means the specifications for the Products as set forth in the Exhibit E or in      the Quality Agreement. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.37.   | “Supply      Failure” shall have the meaning as set forth in Section    3.7.2. |
|---------------------|--------------------------------------------------------------------------------------------|

| 1.1.38.   | “Term”      means, with respect to each country in the Territory, the period      commencing on the Effective Date and ending upon the expiration of the      last-to-expire patent within the Patents in such country, except as and if      sooner terminated in accordance with Article9. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.39.   | “Territory”      means, |
|---------------------|-------------------------------------|

|   | (aa) | Countries      of the Old Agreement, which are: Denmark, Sweden, Norway, Finland,      Estonia, Lithuania, Latvia and |
|--------|------|-----------------------------------------------------------------------------------------------------------------------|

|   | (i) | European      Union countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic,      France, Germany, Hungary, Ireland, Italy, Luxembourg, Malta, Netherlands,      Poland, Romania, Slovakia, Slovenia, United Kingdom,  and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | Russia      and CIS Markets: Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan,      Moldova, Russia, Tajikstan, Ukraine, Uzbekistan and    Kyrgyzstan |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.40.   | “Third      Party” means any Person other than MEDA, ULURU and their respective      Affiliates. |
|---------------------|--------------------------------------------------------------------------------------------------------------|

| 1.1.41.   | “Trademarks”      means all ULURU trademarksOraDiscTM. |
|---------------------|-------------------------------------------------------------------------|

| 1.1.42.   | “ULURU”      has the meaning set forth in thePreamble. |
|---------------------|--------------------------------------------------------------------|

| 1.1.43.   | “ULURU      Confidential Information” means all information, specifications      (including, without limitation, the Specifications), know-how and data      pertaining to the Products and ULURU’s business or its Manufacturing      operations disclosed to MEDA or its Affiliates, Third Party manufacturers      or distributors hereunder, including, without limitation, all information,      Specifications, know-how and data related to the design, implementation,      performance and Manufacture of the Products, and any correspondence with      the FDA, EMEA or any other Regulatory Authority, clinical study data,      analytical data, or operatingprocedures. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2.   | Construction of      Certain Terms and Phrases. |
|------------------|-------------------------------------------------|

----

| 2.   | TERMINATION      OF THE OLD AGREEMENT |
|----------------|---------------------------------------|

| 2.1.   | MEDA      and ULURU hereby terminate by mutual agreement the Old Agreement effective      as of the Effective Date. |
|------------------|---------------------------------------------------------------------------------------------------------------------|

| 2.2.   | The      Parties hereby agree that neither Party shall have any rights and/or      obligations towards the respective other Party resulting from the Old      Agreement and/ or its termination. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | SUPPLY |
|----------------|--------|

| 3.1.   | Grant of License /      Expansion of the Territory. |
|------------------|-----------------------------------------------------|

| 3.1.1.   | Subject      to the terms and conditions of this Agreement, ULURU hereby grants to MEDA      (a) the exclusive right and sub licensable license in the Field under      ULURU’s Intellectual Property Rights to market, offer for sale, sell,      distribute and import products, including the Products, in the Territory,      (b) the exclusive right and sub licensable license in the Field under      ULURU’s Intellectual Property Rights to use the Products in the Territory,      provided that such right and license is limited to such use as is      necessary for MEDA to market, offer for sale, sell, distribute and import      and, subject to the terms and conditions set forth in Section 3.8,      Manufacture the Products in the Territory, and (c) a exclusive right and      sub licensable license to use the Products and all information and      Intellectual Property Rights with respect thereto (including, without      limitation, data, studies and clinical trials) solely for the purpose of      obtaining Regulatory Approvals for the Products. Except as expressly      granted herein, ULURU retains all rights in the Intellectual Property      Rights and the Products. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.2.   | Except      as specifically provided to the contrary in Section 3.1.1, the license      granted in Section 3.1.1 shall not be construed (a) to effect any sale of      ULURU ́s Intellectual Property Rights or any other proprietary ULURU      technology; (b) subject to the terms and conditions set forth in Section      3.8, to grant any license relating to ULURU’s methods of formulating,      fabricating and Manufacturing the Products; (c) to grant MEDA any rights      in or to the use of the Intellectual Property Rights by implication or      otherwise. MEDA shall mark or have marked all containers or packages of      the Products in accordance with the patent marking laws of the      jurisdiction in which such units of Products are to be used or      distributed. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.3.   | Upon      expiration of the Term in any country due to (i)the expiration of the      last-to-expire patent within the Patents in such country or (ii) due to a      termination of the Agreement for cause by MEDA in accordance with the      provisions of Section 3.7.3, 9.4 and/or 9.5, MEDA shall have a      non-exclusive, transferable, timely unrestricted license to those licenses      set forth in Section 3.1.1, provided that MEDA will pay to ULURU the      royalties in accordance with Articles 3.1.3 a)- d) of this      Agreement: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a) | In      consideration for the license granted by ULURU to MEDA as set out above in      Article 3.1.3, MEDA shall pay to ULURU a royalty of 5 % (five percent) on      Net Sales of the Products. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | MEDA      will pay to ULURU the royalties quarterly (meaning any calendar quarter      ending on 31st March, 30th June, 30th September or 31st December) within      30 (thirty) days after the end of the relevant calendar quarter. The      currency of the royalty payment shall be EURO. Each royalty payment shall      be accompanied by a statement in a form as set forth in Article      3.9.3 d) of this Agreement. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | The      rights and obligations of the Parties as to ULURU ́s right to inspect and      examine MEDA ́s books - as laid down in Article 6.5.2 and 6.5.3 of this      Agreement shall - applyaccordingly. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | It      is understood that MEDA ́s obligation to pay royalties to ULURU shall cease      on a product by product basis upon the expiration of the last-to-expire      patent within the Patents in suchcountry. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.1.4.   | MEDA      is free to decide whether (i) to use the Trademarks in the countries of      the Territory or (ii) to register, at MEDA’s expense, and to use      alternative MEDA Trademarks for the promotion, distribution and sale of      the Products. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | a) | Trademarks |
|--------|----|------------|

|   | b) | MEDA      Trademarks |
|--------|----|----------------------|

----

| 3.1.5.   | ULURU      will provide commercially reasonable efforts to re-acquire from Esteve SA,      Spain the exclusive rights for the Manufacture, marketing, promotion, sale      and distribution of the Products in Spain, Greece and Portugal. ULURU will      promptly inform MEDA once the rights had been re-acquired from Esteve SA.      In such a case, the parties agree to extend the Territory and to add      Spain, Greece and Portugal to this Agreement. The Parties will stipulate      the extension of the Territory in an amendment to this Agreement. To avoid      any misunderstandings, the license payments applicable for Spain mentioned      in Exhibit      I are subject to ULURU ́s successful re-acquisition of the Product      rights for Spain, Greece andPortugal. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2.   | Registration of the      Products / RegulatoryApprovals |
|------------------|---------------------------------------------------------|

| 3.2.1.   | At      MEDA’s sole expense, MEDA agrees to make and maintain all Regulatory      Approvals for the Products from the Regulatory Authorities in the      countries of the Territory. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2.2.   | ULURU      will provide MEDA with all documentation which is necessary for the      registration process and the obtaining of the Regulatory Approvals,      including but not limited to a certificate of pharmaceutical product      (“CPP”) and the US dossiers of the Products. ULURU will use commercially      reasonable efforts to assist MEDA in the obtainment of the Regulatory      Approvals. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2.3.   | If      MEDA decides not to register OraDiscTM A (amlexanox) in one of the Major      Countries, the rights to the respective Product (and only to this Product)      in the respective country granted by ULURU according to Section 3.1 shall      revert to ULURU. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2.4.   | Any      Regulatory Approval shall become, if legally permitted in the respective      country of the Territory, the sole property of MEDA. MEDA shall be (if      legally permitted in the respective country of the Territory) the holder      of the Regulatory Approvals. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3.   | Manufacture. |
|------------------|--------------|

| 3.3.1.   | Subject      to Section 3.4, ULURU shall Manufacture and deliver the Products to MEDA      in such quantities and at such times as ordered by MEDA in accordance with      this Agreement. During the Term, ULURU shall maintain the resources      necessary to Manufacture the Products and shall provide, at its own      expense, all Materials and labor necessary to do  so. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3.2.   | ULURU      may not transfer its Manufacturing and supply obligations under this      Agreement to any Third Party without MEDA’s prior written consent. In any      case, ULURU is solely responsible towards MEDA for the fulfillment of all      of ULURU’s Manufacturing and supply obligations under this      Agreement. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3.3.   | MEDA      herewith approves the Third Party manufacturer of ULURU mentioned in Exhibit      B. |
|--------------------|------------------------------------------------------------------------------------------------|

| 3.3.4.   | If      requested by MEDA, ULURU shall be responsible for (a), at MEDA’s cost and      expense, supplying to MEDA, prior to the commencement of Manufacturing of      the Product, a full scale validation Batch and the data reasonably      requested by MEDA (including, without limitation, the final Product      formulation, the processing requirements from start to finish for all      production, the validated analytical methods, the Specifications and test      method (both chemical and physical) for all elements of the disc component      and the Product through the finished production of the Products and the      validation protocols and schedules for processes, equipment, cleaning and      packaging) and MEDA shall reimburse ULURU for ULURU’s actual, reasonable,      out-of-pocket costs for the supply of such Batch and data, (b) at MEDA ’s      cost and expense, scale-up, validation and stability of the Products for      commercial production of the Products, including, without limitation, bulk      production of the benzocaine gel, production of the mucoadhesive disc and      development and validation of a mutually acceptable package configuration,      (c) cooperating with MEDA with respect to the obtaining by MEDA of any      Regulatory Approvals required to be obtained by MEDA with respect to the      marketing, sale, offering to sell, importing and/or distribution of the      Product, and (d) providing to MEDA complete Batch records for all      validation Batches and, on an annual basis, providing one representative      full Batch record. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4.   | Forecasts. |
|------------------|------------|

----

| 3.5.   | Orders and      Delivery. |
|------------------|---------------------------|

| 3.6.   | Shelf      Life. |
|------------------|------------------|

| 3.7.   | Supply      Failures. |
|------------------|-----------------------|

| 3.7.1.   | It      is of essence to this Agreement that ULURU delivers the Products at the      date stated in the purchase order. In the event that ULURU fails to      deliver the Products on or before the delivery date specified in the      applicable purchase order, ULURU or its Affiliates shall notify MEDA of      such delay and the Parties shall consult in good faith to determine the      period of such inability to supply suchProduct. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.7.2.   | If      (i) MEDA reasonably determines that such or any other inability to so      supply a Product will continue for more than 90 (ninety) days, or (ii) if      ULURU fails to supply any of MEDA ́s purchase orders for Product and fails      to cure such failure within 60 (sixty) days after the requested delivery      date therefore (each of (i) and (ii) shall be referred to as a “Supply      Failure”), then MEDA may, at its option either (x) agree to have ULURU      supply the undelivered Product at a future date agreed upon the Parties or      (ii) have up to 100 (hundred) % supplied by a secondary supplier of such      Product as provided for in Article 3.8below. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.7.3.   | If      ULURU continues to be delayed with the delivery of the Products for a      period of six (6) consecutive months, MEDA has, without any time      restriction, the right to terminate this  Agreement. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.8.   | Secondary      Supplier: |
|------------------|--------------------------|

| 3.8.1.   | MEDA      shall have the right to establish and maintain secondary supplier (s) for      all Products (in finished form). MEDA and UULURU shall jointly select and      agree on a secondary supplier(s), provided however that if the Parties can      not agree on a secondary supplier, then MEDA shall be entitled to appoint      a secondary supplier at its solediscretion. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.8.2.   | ULURU      shall cooperate with MEDA in the transfer of copies of the ULURU      Confidential Information, technology and know- how necessary to      Manufacture the Products to MEDA and/or its designated secondary supplier      (s), (b) deliver to MEDA copies of such drawings, specifications, and      other information in ULURU’s possession as may be necessary to Manufacture      the Products or cause the Products to be Manufactured and (c) grant to      MEDA a limited license in the Field under ULURU’s Intellectual Property      Rights during the Term of this Agreement to Manufacture, make, or have      made for MEDA’s distribution of the Product in the Territory, the      Products; provided that to the extent that such technology and know-how      constitutes ULURU Confidential Information (or any information constitutes      Confidential Information of ULURU’s Third Party manufacturer) it shall be      subject to the provisions of Article 10 and MEDA’s designated secondary      supplier shall be required to enter into a confidentiality agreement with      ULURU containing substantially the same terms as Article 10; and further      provided that all items provided under clauses (a) and (b) above will be      subject to the license granted pursuant to clause  (c). |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.8.3.   | Subject      to Section 3.8.1 following the establishment of any secondary supplier      hereunder, MEDA may obtain from such secondary supplier such portion of      its supplier requirements with the respect to the Product as is necessary      to maintain such secondary supplier’s regulatory qualification, but in no      event more than 10% of MEDA ́s total requirements for the Products. Product      procured until this section 3.8.3 will be subject to a royalty of 5% of      Net Sales in the Territory. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.8.4.   | Notwithstanding      the provisions of Section 3.8.3 above, but subject to Section 3.8.1 above,      MEDA shall have the right to obtain from such secondary supplier(s) up to      100% of its supply requirements with respect to any Products in the event      (a) of expiration of the Term of this Agreement or (b) MEDA terminates the      Agreement with respect to such Product pursuant to Article 3.7.4, 9.4 and      9.5 of this Agreement, (c) in the event of a Supply Failure occurs with      respect to such Product. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.9.   | Marketing, Promotion      and Distribution. |
|------------------|---------------------------------------------|

| 3.9.1.   | ULURU      agrees that MEDA shall have only the obligation to market, promote, sell      and distribute OraDiscTM A (amlexanox) in the countries of the Major      Countries, Belgium, the Netherlands and in Turkey, provided that, nothing      shall require MEDA to continue to market or sell the Products in any of      these countries during a period of time that MEDA determines, in its sole      judgment, that such Product is reasonably likely to be Subject to adverse      regulatory or legal action, or infringe any intellectual property right of      any Third Party in such country. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.9.2.   | MEDA      agrees to Launch in addition OraDiscTM A (amlexanox) in the countries of      the Major Countries, Belgium, the Netherlands and in Turkey, within 6      (six) months after Regulatory Approval has been granted, provided that      ULURU has delivered MEDA with Products as laid down in the respective      purchase order. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.9.3.   | Subject      to Section 3.9.1 – 3.9.2 above, MEDAagrees |
|--------------------|---------------------------------------------------------------|

| 3.9.4.   | ULURU      agrees to support MEDA, as far as possible for and available within ULURU,      in the promotion, marketing, sale and/or distribution of the Products in      the Territory. Any costs related to such support will be borne by MEDA. If      possible (i.e. where marketed by ULURU’s partners e.g. USA), ULURU will      provide MEDA with examples of promotional material from its sub-licensees      and distributors. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.10.   | Supply of      Samples |
|-------------------|------------------------|

| 3.11.   | Clinical trials /      Clinical Data |
|-------------------|--------------------------------------|

| 3.11.1.   | If      (i) the Parties mutually agree to conduct further clinical trials and/or      (ii) if a clinical trial is required for regulatory approval purposes,      ULURU will contribute fifty (50%) per cent towards the cost of the      respective clinical trial. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.11.2.   | MEDA      shall have the right to use and reference all clinical and other technical      data generated by ULURU and ULURU’S licensees relating to the Products.      ULURU and its licensees shall have the right to use and reference all      clinical and other technical data generated by MEDA relating to      Products. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.12.   | Additional      Responsibilities |
|-------------------|----------------------------------|

| 3.12.1.   | MEDA      shall be responsible, at MEDA’s cost and expense, for any consumer product      testing and commercialization of the Products, including, without      limitation, all sales and marketing activities related to the Products and      the design of all Product packaging and related artwork, and the design of      all labeling. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.12.2.   | MEDA      shall retain, at its own expense a selling and service organization with      adequate experience, ability and training for purposes of marketing and      selling the Products in theTerritory. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4.   | COMPLIANCE,      QUALITY AND ENVIRONMENTAL |
|----------------|--------------------------------------------|

| 4.1.   | Compliance with      Law. |
|------------------|---------------------------|

| 4.2.   | Manufacturing Quality;      Storage. |
|------------------|--------------------------------------|

| 4.2.1.   | All      Products shall be Manufactured by ULURU at the Facilities using Materials      and processing aids free of animal derived materials. ULURU shall sample      and analyze all Materials upon receipt to ensure that such Materials are      unadulterated, free of defects and meet the applicable Specifications      therefore. ULURU shall take all necessary steps to prevent contamination      and cross contamination ofProducts. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2.2.   | The      Products shall be unadulterated and free from contamination, dilutents and      foreign matter in any amount and in accordance with the Product      specifications and generally accepted pharmaceutical standards. ULURU      shall perform the quality control tests (both when the Product is      in-process and when it is finished) with respect to the Products in      accordance with the Methods of Analysis, the cost of such to be included      in the price hereinafter specified. ULURU shall promptly, upon completion      of such tests, deliver to MEDA a copy of the record of such tests      performed on, and a Certificate of Analysis for, each Batch of Product.      ULURU shall deliver a representative sample from each Batch of Product to      MEDA’s designated representative by the date reasonably specified by such      representative. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2.3.   | Within      sixty (60) days of the Effective Date, each of the Parties shall execute      and deliver the Quality Agreement substantially in the form of Exhibit C and      as mutually agreed to by the parties.  Each Party agrees to      perform its respective obligations under the Quality Agreement in      accordance with such agreement.  Prior to shipment, the Products      shall be stored at all times in conditions at least as favorable as those      set forth on the Product’s label, or in accordance with conditions      reasonably specified by MEDA. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3.   | Testing by      MEDA. |
|------------------|-----------------------|

| 4.4.   | Samples and Record      Retention. |
|------------------|------------------------------------|

----

| 4.5.   | Inspection. |
|------------------|-------------|

| 4.6.   | Adverse Drug Events /      Pharmacovigilance Agreement. |
|------------------|---------------------------------------------------------|

| 4.6.1.   | Each      Party shall fully, accurately and promptly provide the other Party with      all data known to it at any time during the Term of this Agreement or      thereafter, which data indicate that any Product is or may be unsafe,      lacks utility, or otherwise does not meet the    Specifications. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6.2.   | Within      sixty (60) days of the Effective Date, each of the Parties shall execute      and deliver the Pharmacovigilance Agreement substantially in the form of      Exhibit G      and as mutually agreed to by the parties. Each Party agrees to perform its      respective obligations under the Pharmacovigilance Agreement in accordance      with such agreement. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.7.   | Recalls and      Seizure. |
|------------------|---------------------------|

| 4.7.1.   | Each      Party shall keep the other Party promptly and fully informed of any      notification or other information whether received directly or indirectly      which might result in the Recall or Seizure of the Products. If either      Party determines that it is necessary to Recall any Product, it shall      immediately notify the other Party and, prior to commencing any Recall,      the Parties shall consult with one another to determine whether or not a      Recall is necessary. If it is mutually agreed that a Recall is necessary      (or if MEDA determines, in its sole discretion, that a Recall is      necessary), then the Parties shall meet and determine the manner in which      the Recall is to be carried out and review any instructions or suggestions      of the applicable Regulatory Authorities. MEDA and ULURU shall effect the      Recall in the manner agreed upon between the Parties in as expeditious a      manner as possible and in such a way as to cause the least disruption to      the sales of any Product and to preserve the goodwill and reputation      associated with the Product. In any such situation, MEDA shall have the      right to make all final decisions regarding such  Recall. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.7.2.   | In      the event that a Recall results from any cause or event arising from      ULURU’s breach of Sections 4.1, 4.2, 4.4, 4.6. 4.8 or the representations      set forth in Sections 7.2.1, 7.2.4 or 7.2.5 and/or the defective      Manufacture, storage or handling of the Products by ULURU (excluding      defects relating to packaging or labeling supplied by or prepared at and      in accordance with the direction of MEDA), ULURU shall be responsible for      all expenses of the Recall incurred by MEDA and ULURU shall promptly      replace such Product at no additional cost to MEDA consistent with      directions received from the appropriate Regulatory Authority. In the      event that a Recall results from any cause or event arising from defective      Manufacture, storage, handling or distribution of the Products by MEDA or      its Affiliates, distributors or contractors (including but not limited to      defective Manufacture, storage, handling or distribution undertaken at the      direction of MEDA and consistently with MEDA’s instructions), MEDA shall      be responsible for the expenses of the Recall, including the cost of      replacement Product. For the purposes of this Agreement, the expenses of a      Recall shall include, without limitation, the expenses of notification and      destruction or return of the recalled Product and all other costs incurred      in connection with such Recall, including reasonable costs and attorneys’      fees, but shall not include lost profits of either  party. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.8.   | Environmental,      Occupational Health andSafety. |
|------------------|----------------------------------------------------|

| 4.8.1.   | ULURU      shall promptly report to MEDA after any of the following incidents related      to the Manufacturing operations hereunder occurs: (a) fatalities and/or      significant injuries or occupational illness; (b) property damage in      excess of € 50,000; (c) inspections by any environmental protection      agency or occupational health and safety agency; or (d) requests for      information, notices of violations or other significant governmental and      safety agency communications relating to environmental, occupational      health and safety compliance. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 5.   | MANUFACTURING      CHANGES |
|----------------|----------------------------|

| 5.1.   | Voluntary      Changes. |
|------------------|-------------------------|

| 5.2.   | Required      Changes. |
|------------------|------------------------|

| 6.   | PRICE      AND PAYMENT |
|----------------|------------------------|

| 6.1.   | Prices for the      Products. |
|------------------|-------------------------------|

| 6.1.1.   | The      prices for the Products are set forth in Exhibit H. The      prices include all Manufacturing and supply obligations of ULURU under      this Agreement. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.1.2.   | The      prices shall be fixed for the Term of this Agreement, if not otherwise      stipulated in Section 6.1.3 below. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------|

| 6.1.3.   | ULURU      shall be entitled to revise the prices of the Products in case that      ULURU’s labor costs and/or Material costs will increase by more than 21⁄2%      (two and one-half percent) compared to the costs/prices valid at the      Effective Date, provided however that (i) ULURU will prove the increase in      writing and (ii) MEDA ́s gross margin will not be below 70 (seventy) % and      (iii) MEDA ́s prices for the products are not worse than the prices for the      products to other licensees inEurope. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.   | License      payments. |
|------------------|------------------------|

| 6.3.   | Payment. |
|------------------|----------|

| 6.4.   | Taxes and Other      Charges. |
|------------------|-------------------------------|

----

| 6.5.   | Audit      Rights. |
|------------------|--------------------|

| 6.5.1.   | MEDA      shall have the right, at its own expense, to access the books and records      of ULURU and its Affiliates as may be reasonably necessary to verify the      accuracy of the labor costs and Material costs referred to in Section      6.1.3. Such access shall be conducted after thirty (30) days’ prior      written notice to ULURU and during ordinary business hours, will be      conducted in a manner that is not disruptive to ULURU’s operations, and      shall not be more frequent than once per Contract Year or in respect of      any Contract Year ending not more than twenty-four (24) months prior to      the date of such notice. Subject to Section 6.5.3, if such independent      certified public accountant’s report shows any overpayment by MEDA, ULURU      shall remit to MEDA within thirty (30) days after MEDA’s receipt of such      report, (a) the amount of such overpayment, and (b) if such overpayment      exceeds three percent (3%) of the total amount owed for the period then      being audited, the reasonable fees and expenses of any independent      accountant performing the audit on behalf of MEDA. Subject to Section      6.5.3., if such independent certified public accountant’s report shows any      underpayment by MEDA, MEDA shall pay to ULURU within thirty (30) days      after MEDA’s receipt of such report, the amount of such underpayment. Any      audit or inspection conducted under this Agreement by MEDA or its agents      or contractors will be subject to the confidentiality provisions of this      Agreement, and MEDA will be responsible for compliance with such      confidentiality provisions by such agents or  contractors. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.5.2.   | MEDA      shall maintain books of account with respect to its sales of the Products      in each country in the Territory. ULURU shall have the right, not more      than once during each Calendar Year, to have an independent accountant      selected and retained by ULURU to inspect and examine such books of MEDA      during regular business hours for the purpose of verifying the statements      of the aggregate Net Sales resulting from sales of Products and      determining the correctness of the date of the license payments paid (or      not yet paid). If such independent certified public accountant’s report      shows any (i) underpayment by MEDA, or (ii) late payment by MEDA (due to      the fact that the cumulated Net Sales set fort in the Exhibit I      (license payment no. 4) had been achieved earlier), MEDA shall pay to      ULURU within thirty (30) days after MEDA ́s receipt of such report, (a) the      amount of such underpayment or late payment, and (b) if such (y)      underpayment exceeds five percent (5%) of the total amount owed for the      period then being audited or (z) late payment is more than three (3)      months past due, the reasonable fees and expenses of any independent      accountant performing the audit on behalf of ULURU. Otherwise, ULURU has      to bear the costs of the independent accountant. Any audit or inspection      conducted under this Agreement by ULURU or its agents or contractors will      be subject to the confidentiality provisions of this Agreement, and ULURU      will be responsible for compliance with such confidentiality provisions by      such agents or contractors. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.5.3.   | If      any dispute arises under this Section 6.5 between the Parties relating to      overpayments, underpayments or late payments, and the Parties cannot      resolve such dispute within thirty (30) days of a written request by      either Party to the other Party, the Parties shall hold a meeting,      attended by the Chief Executive Officer or President of each Party (or      their respective designees), to attempt in good faith to negotiate a      resolution of the dispute. If, within sixty (60) days after such meeting      request, the Parties have not succeeded in negotiating a resolution of the      dispute, either Party may pursue any other available remedy, including,      upon prior written notice to the other Party, instituting legal      action. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.6.   | Late      Payments. |
|------------------|---------------------|

| 6.7.   | Currency      Exchange. |
|------------------|-------------------------|

----

| 7.   | REPRESENTATIONS      AND WARRANTIES |
|----------------|-------------------------------------|

| 7.1.   | Representation and      Warranties of Each Party. |
|------------------|---------------------------------------------------|

| 7.1.1.   | it      is a corporation or entity duly organized and validly existing under the      laws of the state or other jurisdiction of incorporation or      formation; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.1.2.   | the      execution, delivery and performance of this Agreement by such Party has      been duly authorized by all requisite corporate action and do not require      any shareholder action or approval; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.1.3.   | it      has the power and authority to execute and deliver this Agreement and to      perform its obligations hereunder; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------|

| 7.1.4.   | the      execution, delivery and performance by such Party of this Agreement and      its compliance with the terms and provisions hereof does not and will not      conflict with or result in a breach of any of the terms and provisions of      or constitute a default under (a) a loan agreement, guaranty, financing      agreement, agreement affecting a product or other agreement or instrument      binding or affecting it or its property; (b) the provisions of its charter      or operative documents or by laws; or (c) any order, writ, injunction or      decree of any court or governmental authority entered against it or by      which any of its property is bound;and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.1.5.   | it      shall comply with all applicable laws and regulations relating to its      activities under this Agreement. |
|--------------------|---------------------------------------------------------------------------------------------------------------------|

| 7.2.   | Representations and      Warranties of ULURU. |
|------------------|-----------------------------------------------|

| 7.2.1.   | as      of the date of each delivery of the Product by ULURU to a carrier, the      Products (a) has been Manufactured, stored and shipped in strict      accordance with GMPs, all applicable laws, rules, regulations or      requirements and all applicable Regulatory Approvals in effect at the time      of Manufacture; (b) conforms to the Specifications and the Quality      Agreement, and is free from defects and are merchantable; (c) is not      adulterated or misbranded; and (d) has been stored in accordance with      procedures requested by MEDA; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.2.   | as      of the date of each supply of the Products by ULURU, ULURU has good and      marketable title to the Products and the Products are free from all liens,      charges, encumbrances and securityinterests; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.3.   | to      ULURU’s actual knowledge as of the Effective Date, the Manufacture, use,      importation, offer for sale and sale of the Products does not infringe any      intellectual property rights of any Third Party within the      Territory; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.4.   | as      of the date of each supply of the Products by ULURU, ULURU possesses all      necessary Regulatory Approvals relating to ULURU’s Manufacture and supply      to MEDA of the Products; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.5.   | as      of the Effective Date, the Patents are existing and have not been held to      be invalid or unenforceable, in whole or in  part; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.6.   | as      of the Effective Date, ULURU is the sole and exclusive owner of the      Intellectual Property Rights existing as of the Effective Date, all of      which are free and clear of any liens, charges and encumbrances (other      than any licenses granted by ULURU to Third Parties, which grants do not      conflict with the license grants to MEDA  hereunder); |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.7.   | as      of the Effective Date, and, except as disclosed to MEDA in writing, as of      the date of each supply of the Products by ULURU, ULURU has received no      notice that the practice of the Intellectual Property Rights or the      Trademarks are subject to an infringement claim of any issued patent or      Trademark owned or possessed by any Third Party within the      Territory; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.8.   | as      of the Effective Date, the Intellectual Property Rights are not the      subject to any funding agreement with any government or governmental      agency; and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.9.   | as      of the Effective Date, or within ten (10) days thereof, ULURU has provided      MEDA with any and all information relating to the Products, its      Manufacture and formulation necessary for MEDA to conduct a freedom to      operate opinion relating to the Territory, and all information has been      provided so that MEDA may complete its due  diligence. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3.   | No      Presumption. |
|------------------|----------------------|

----

| 7.4.   | Remedy. |
|------------------|---------|

| 7.5.   | MEDA      Responsibility. |
|------------------|---------------------------|

| 7.6.   | Disclaimer. |
|------------------|-------------|

| 7.6.1.   | THE      FOREGOING WARRANTIES ARE THE SOLE AND EXCLUSIVE WARRANTIES GIVEN BY ULURU      WITH RESPECT TO THE PRODUCTS AND SERVICES PROVIDED HEREUNDER, AND ULURU      GIVES AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR      IMPLIED, OTHER THAN THE FOREGOING. WITHOUT LIMITING THE GENERALITY OF THE      FOREGOING, EXCEPT FOR THE WARRANTIES EXPRESSLY PROVIDED IN SECTION 6, NO      IMPLIED WARRANTY OF MERCHANTABILITY, VALIDITY, NON-INFRINGEMENT, TITLE,      FITNESS FOR ANY PARTICULAR PURPOSE, AND NO IMPLIED WARRANTY ARISING BY      USAGE OF TRADE, COURSE OF DEALING OR COURSE OF PERFORMANCE IS GIVEN OR      MADE BY ULURU OR SHALL ARISE BY OR IN CONNECTION WITH ANY SALE OR      PROVISION OF PRODUCTS OR SERVICES BY ULURU, OR MEDA’S USE OR SALE OF THE      PRODUCT, OR ULURU’S AND/OR MEDA’S CONDUCT IN RELATION THERETO OR TO EACH      OTHER. NO REPRESENTATIVE OF ULURU IS AUTHORIZED TO GIVE OR MAKE ANY OTHER      REPRESENTATION OR WARRANTY OR TO MODIFY THE FOREGOING WARRANTY IN ANY      WAY. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.6.2.   | EXCEPT      FOR THE WARRANTIES GIVEN BY MEDA AS EXPRESSLY PROVIDED IN ARTICLE 7, MEDA      GIVES AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE,      EXPRESS OR IMPLIED, WITH RESPECT TO THE MATTERS ADDRESSED IN THIS      AGREEMENT. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.6.3.   | The      warranties set forth in this Article 7 do not apply to any nonconformity      of the Product resulting from (a) repair, alteration, misuse, negligence,      abuse, accident, mishandling or storage in an improper environment by any      party other than ULURU (or its contract manufacturer), or (b) use,      handling, storage or maintenance other than in accordance with Product      Specifications or Product label. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7.   | Limitation of      Liability. |
|------------------|-------------------------------|

----

| 8.   | INDEMNIFICATION      AND INSURANCE |
|----------------|------------------------------------|

| 8.1.   | Indemnification. |
|------------------|------------------|

| 8.1.1.   | ULURU      shall defend, indemnify and hold harmless MEDA, its Affiliates, directors,      officers, employees and agents from and against all damages, losses,      liabilities, expenses, claims, demands, suits, penalties or judgments or      administrative or judicial orders (including, without limitation,      reasonable attorneys’ fees and expenses) incurred, assessed or sustained      by or against MEDA, its Affiliates, directors, officers, employees or      agents with respect to a claim by a Third Party arising out of (a) the      negligent acts or omissions of ULURU; (b) any breach by ULURU of this      Agreement or its representations, warranties or covenants hereunder; (c)      any Recall or Seizure attributable to ULURU’s performance (including,      without limitation, amounts MEDA pays or credits to its customers for      Products so Recalled or Seized); (d) product liability, tort, nuisance or      other claim arising out of the defective manufacture, storage or supply of      the Products by ULURU; (e) any allegation that the Manufacture,      importation, sale, offer for sale or use of the Products infringe any      patent or other intellectual property, proprietary or protected right      within the Territory; provided that ULURU will not be obligated to      indemnify MEDA if and to the extent that the alleged infringement is      caused by: (i) MEDA’s (including, without limitation, its Affiliates,      agents, contractors, and sub-distributors) or its customers misuse or      modification of the Products; or (ii) MEDA’s (including, without      limitation, its Affiliates, agents, contractors, and sub- distributors) or      its customers use of the Products in combination with any products or      materials not provided by ULURU; and further provided that if the Product      is held to constitute an infringement or misappropriation of any Third      Party’s intellectual property rights or if in ULURU ́s opinion, the      Products are, or is likely to be held to constitute, an infringement or      misappropriation, ULURU may at its expense and option: (x) procure the      right for MEDA to continue distributing the Products (y) upon prior      approval by MEDA, which approval will not be unreasonably withheld or      delayed, promptly replace the Product with a non-infringing and      non-misappropriating equivalent product conforming to the applicable      Product Specifications and Regulatory Approvals; provided that there shall      not be any material delay in any such replacement; or (z) upon prior      approval by MEDA, which approval will not be unreasonably withheld or      delayed, modify the Product to make it non-infringing and      non-misappropriating while conforming to the applicable Product      Specifications and Regulatory Approvals; provided that there shall not be      any material delay in any such modification; (f) any enforcement or other      action by any Regulatory Authority relating to the Manufacture, the      pricing of the Products by ULURU to MEDA or sale of the Products by ULURU      to MEDA, or (f) ULURU’s failure to comply with any applicable law,      regulation or order (including, without limitation, environmental laws,      regulations and orders). The foregoing indemnification obligation shall      not apply in the event and to the extent that such claim arose as a result      of any indemnitee’s negligence, intentional misconduct or breach of this      Agreement. The provisions of this Section shall survive the termination or      expiration of this Agreement. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.1.2.   | MEDA      shall defend, indemnify and hold harmless ULURU, its directors, officers,      employees and agents from and against all damages, losses, liabilities,      expenses, claims, demands, suits, penalties or judgments or administrative      or judicial orders (including, without limitation, reasonable attorneys’      fees and expenses) incurred, assessed or sustained by or against ULURU,      its directors, officers, employees or agents with respect to a claim by a      Third Party arising out of (a) the negligent acts or omissions of MEDA;      (b) any breach by MEDA of this Agreement or of its representations,      warranties or covenants hereunder; (c) any allegation that the Trademarks      or MEDA’s packaging or MEDA’s (or any Affiliate of MEDA’s) marketing      materials infringes any patent or other proprietary or protected right of      any Third Party; (d) any Recall or Seizure attributable to MEDA’s      performance; (e) any enforcement or other action by any Regulatory      Authority relating to the distribution or the pricing of the Products by      MEDA or sale of the Products by MEDA to Third Parties; (f) MEDA’s failure      to comply with any applicable law, regulation or order (including, without      limitation, environmental laws, regulations and orders), or (g) the      marketing and distributing of the Products by MEDA, its Affiliates or      sub-distributors. The foregoing indemnification obligation shall not apply      in the event and to the extent that such claim arose as a result of any      indemnitee’s negligence, intentional misconduct or breach of this      Agreement. The provisions of this Section shall survive the termination or      expiration of this Agreement. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.1.3.   | To      receive the benefit of indemnification under this Section 8.1, the Party      and its Affiliates, directors, officers, employees or agents seeking      indemnification (an “Indemnified Party”) shall promptly notify the other      Party (the “Indemnifying Party”), in writing, of any claim asserted or      threatened against such Indemnified Party for which such Indemnified Party      is entitled to indemnification hereunder from the Indemnifying Party. With      respect to any such claim the Indemnified Party shall, at no out-of-pocket      expense to it, reasonably cooperate with and provide such reasonable      assistance to such Indemnifying Party as such Indemnifying Party may      reasonably request. Such reasonable assistance may include, without      limitation, providing copies of all relevant correspondence and other      materials that the Indemnifying Party may reasonably request. The      obligations of an Indemnifying Party under Sections 8.1.1 and 8.1.2 are      conditioned upon the delivery of written notice to the Indemnifying Party      of any asserted or threatened claim promptly after the Indemnified Party      becomes aware of such claim; provided that the failure of the Indemnified      Party to give such notice or any delay thereof shall not affect the      Indemnified Party’s right to indemnification hereunder, except to the      extent that such failure or delay impairs the Indemnifying Party’s ability      to defend or contest any such claim. The Indemnifying Party shall have the      right to assume the defense of any suit or claim for which indemnification      is sought with counsel reasonably acceptable to the Indemnified Party. If      the Indemnifying Party defends the suit or claim, the Indemnified Party      may participate in the defense thereof at its sole cost and expense. An      Indemnifying Party may not settle a suit or claim without the consent of      the Indemnified Party if (a) such settlement would impose any monetary      obligation on the Indemnified Party for which indemnification is not      provided hereunder, (b) or require the Indemnified Party to submit to an      injunction or otherwise limit the Indemnified Party’s rights under this      Agreement, or (c) does not include a release of the Indemnified Party from      all liability arising out of such suit or claim. Any payment made by an      Indemnifying Party to settle any such suit or claim shall be at its own      cost and expense. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.1.4.   | The      indemnification provided by this Article 8 shall be the Parties’ sole and      exclusive remedy in connection with any third party  claim. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.   | Insurance. |
|------------------|------------|

| 8.2.1.   | At      the time of Launch and continuing through the Term of this Agreement,      ULURU shall have and maintain sufficient insurance coverage of any and all      common insurances regarding the Manufacture and supply of the Products,      including but not limited to Commercial General Liability including      Contractual, Completed Operations and Product  Liability. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.2.   | Upon      request of MEDA, ULURU shall prove the execution of the insurances and      their maintenance by demonstrating a written approval of the      insurer. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.   | TERM      AND TERMINATION |
|----------------|---------------------------|

| 9.1.   | Term. |
|------------------|-------|

| 9.2.   | Termination Without      Cause. |
|------------------|---------------------------------|

| 9.3.   | Termination for      Regulatory Action or Claim of  Infringement. |
|------------------|-------------------------------------------------------------------|

| 9.4.   | Termination for      Breach. |
|------------------|------------------------------|

| 9.5.   | Termination for      Bankruptcy. |
|------------------|----------------------------------|

| 9.6.   | Effect of      Termination. |
|------------------|-----------------------------|

| 9.7.   | MEDA’s Rights on      Termination. |
|------------------|------------------------------------------|

| 9.8.   | Survival. |
|------------------|-----------|

----

| 10.   | CONFIDENTIALITY |
|-----------------|-----------------|

| 10.1.   | Nondisclosure      Obligation. |
|-------------------|--------------------------------|

| 10.2.   | Permitted      Disclosures. |
|-------------------|-----------------------------|

| 10.3.   | Disclosure of      Agreement. |
|-------------------|-------------------------------|

| 10.4.   | Publicity. |
|-------------------|------------|

----

| 11.   | FORCE      MAJEURE |
|-----------------|--------------------|

| 12.   | INTELLECTUAL      PROPERTY |
|-----------------|----------------------------|

| 12.1.   | MEDA Trademarks; MEDA      Intellectual Property. |
|-------------------|---------------------------------------------------|

| 12.1.1.   | MEDA      may advertise, promote, market and sell the Products either separately or      as part of other products under any of the MEDA Trademarks and/or trade      dress, whether registered or unregistered, in its sole discretion;      provided that except as otherwise expressly permitted under Section 3.1.4      with respect to the Trademark, MEDA may not use or adopt any Trademark or      trade dress, or any such item confusingly similar thereto used or intended      to be used prior to the first use of such Trademark. ULURU shall have no      right, title or interest in or to any such MEDA Trademark or trade dress,      and MEDA shall have no right, title or interest in or to any such      Trademark (except for the license to the Trademark granted under Section      3.1.4). So long as MEDA or any Affiliate of MEDA shall have any interest      in any such MEDA Trademark or trade dress, whether registered or      unregistered, whether as proprietor, owner, or licensee in any country of      the world, ULURU shall not adopt, use, apply for registration, register or      own such MEDA Trademark or trade dress, or any such item confusingly      similar thereto in any country of the world, or take any action which      weakens or undermines MEDA’s proprietary rights therein. So long as ULURU      or any Affiliate of ULURU shall have any interest in any such Trademark or      trade dress, whether registered or unregistered, whether as proprietor,      owner, or licensee in any country of the world, except as otherwise      expressly permitted under Section 3.1.4 with respect to the Trademark,      MEDA shall not adopt, use, apply for registration, register or own such      Trademark or trade dress, or any such item confusingly similar thereto in      any country of the world, or take any action which weakens or undermines      ULURU’s proprietary rights therein. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.2.   | For      the avoidance of doubt, MEDA shall at all times retain sole and exclusive      ownership of its intellectual property, including, without limitation, all      marketing and sales plans, artwork, formats, equipment, logos, drawings,      customer lists, regulatory filings, correspondence with the EMEA or any      other Regulatory Authority, clinical study data, analytical data,      operating procedures, MEDA Trademarks and all ordering and sales      information. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.2.   | Inventions. |
|-------------------|-------------|

| 12.2.1.   | Except      as otherwise provided for in this Section 12.2, each Party shall own all      Inventions made solely by employees of such Party (or Third Parties acting      on behalf of such Party) and shall jointly own with the other Party any      Invention made jointly by employees of both Parties (or Third Parties on      behalf of one or both Parties); provided that such Inventions were made      without violation of any term or condition of this Agreement. All      determinations of inventorship under this Agreement shall be made in      accordance with the laws applicable in the respective country where the      employee made the respectiveinvention.. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.2.   | If      and to the extent applicable, Inventions Controlled by ULURU and know-how      arising during the Term which relates to the Products and is Controlled by      ULURU shall be automatically included in the Intellectual Property Rights      under which MEDA is licensed pursuant to Section 3.1.1 hereof. With      respect to any Inventions or know-how Controlled by MEDA specifically      relating to the Products, MEDA hereby grants to ULURU an exclusive      (subject to retained rights in MEDA), royalty-free license to use such      Invention for the Manufacture of the Products for MEDA in the Territory      during the Term. However, it is understood that in the event of Article      3.8.3 and 3.8.4., a secondary supplier will also be entitled to use such      Invention for the Manufacture of the Products for MEDA without any      additional costs, provided that this Agreement has not been      terminated. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.3.   | During      the Term of this Agreement both Parties shall require their employees and      personnel involved in the performance of its duties under this Agreement      to deliver such assignments, confirmations of assignments or other written      instruments as are necessary to vest in the respective Party clear and      marketable title to the Inventions. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.4.   | All      rights, title and interest in and to the ULURU Intellectual Property      Rights shall remain exclusively owned by ULURU. The Inventions owned by      ULURU under this Section shall be referred to herein as “ULURU      Inventions”. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.5.   | All      rights, title, and interest in and to know-how, which is developed jointly      by the Parties during the Term of this Agreement and related to the      Products, its Manufacture and/or use shall be owned jointly by the      Parties. All rights, title, and interest in and to any Regulatory Approval      the primary responsibility for which is allocated to a particular Party      hereunder that is developed or collected solely or jointly by the Parties      in the Territory during the Term of this Agreement shall be owned      exclusively by such Party. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.3.   | Confidentiality of      Information related to Intellectual  Property. |
|-------------------|------------------------------------------------------------------------|

----

| 12.4.   | Patent Rights to New      inventions. |
|-------------------|---------------------------------------|

| 12.4.1.   | ULURU,      at its own expense, shall use commercially reasonable efforts to prepare,      file, prosecute and maintain its Intellectual Property Rights in the      countries of the Territory. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4.2.   | With      respect to any filings after the Effective Date, ULURU shall give MEDA a      reasonable opportunity to review and comment upon the text of such      applications in the Territory before filing, shall consult in good faith      with MEDA with respect to such applications in the Territory, and shall      supply MEDA with a copy of such applications in the Territory as filed,      together with notice of its filing date and serial number. ULURU shall      inform MEDA about the status of the prosecution of all patent applications      included within the ULURU Intellectual Property Rights and its      Intellectual Property Rights to Inventions and the maintenance of any      patents included within the ULURU Intellectual Property Rights and its      Intellectual Property Rights to Inventions in a country in the      Territory. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4.3.   | ULURU      shall consult with MEDA and provide MEDA with reasonable opportunity to      comment on all correspondence received from and all submissions to be made      to any Regulatory Authority in the Territory with respect to any such      patent application or patent. ULURU shall consider in good faith, but will      not be bound by, MEDA’s suggestions with respect to all submissions in the      Territory made to any Regulatory Authority in the Territory with respect      to any such patent application orpatent. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4.4.   | If      ULURU elects not to file a patent application with respect to its new      Inventions or to cease the prosecution and/or maintenance of any Patent      under the ULURU Intellectual Property Rights in a country in the      Territory, ULURU shall provide MEDA with written notice promptly after the      decision to not file or continue the prosecution of such patent      application or maintenance of suchpatent. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4.5.   | In      such event, ULURU shall permit MEDA, in MEDA’s sole discretion, to file a      patent application with respect to such Invention or continue prosecution      or maintenance of any such Patent under the ULURU Intellectual Property      Right in such country at MEDA’s own expense. If MEDA elects to continue      such prosecution or maintenance, ULURU shall execute such documents and      perform such acts, at MEDA’s expense, as may be reasonably necessary to      permit MEDA to file, prosecute or maintain such application or Patent in      such country. In such event, MEDA shall own such patent application or      Patent filed by MEDA hereunder. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4.6.   | The      Parties shall mutually agree in good faith on a case-by- case-basis on      which of the Parties shall have the first right to prepare, file,      prosecute and maintain any jointly owned Invention and patent rights      thereon (“Joint Patent Rights”) throughout the world as well as on the      split of the applicable expenses andcosts. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4.7.   | Each      Party shall, and shall cause its Affiliates, employees, attorneys and      agents to, cooperate fully with the other Party and provide all      information and data and execute any documents reasonably required or      requested in order to allow the other Party to prosecute, file, and      maintain patents and patent applications pursuant to this Section 12.4.      Neither Party shall require the other Party to make any payment or      reimburse for any expenses in connection with such cooperation, provision      of information and data and execution of  documents. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.5.   | Enforcement of      Intellectual PropertyRights. |
|-------------------|--------------------------------------------------|

| 12.5.1.   | If      either Party becomes aware of any infringement of any of the Intellectual      Property Rights, the Trademark, the MEDA Trademark or the validity of any      of the Intellectual Property Rights, Trademark or the MEDA Trademark is      challenged by a Third Party in the Territory, such Party will notify the      other Party in writing to that effect. Any such notice shall include, as      applicable, evidence to support an allegation of infringement by such      Third Party. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5.2.   | ULURU      shall have the first right, but not the obligation, to take action to      obtain a discontinuance of infringement or bring suit against a Third      Party infringer of Intellectual Property Rights and/or the Trademark in      the Territory. Such right shall remain in effect until ninety (90) days      after the date of notice given under Section 12.5.1. In the event that      ULURU exercises such right, then: (a) ULURU shall not consent to the entry      of any judgment or enter into any settlement with respect to such an      action or suit without the prior written consent of MEDA (not to be      unreasonably withheld), and (b) ULURU shall bear all the expenses of any      such suit brought by ULURU claiming infringement of any Intellectual      Property Rights and/or the Trademark. If, after the expiration of the      ninety (90) day period, ULURU has not obtained, or is not diligently      pursuing, a discontinuance of infringement of the Intellectual Property      Rights and/or the Mark, filed suit against any such Third Party infringer      of the Intellectual Property Rights and/or the Trademark, or provided MEDA      with information and arguments demonstrating to MEDA’s reasonable      satisfaction that there is insufficient basis for the allegation of such      infringement of the Intellectual Property Rights and/or the Trademark,      then MEDA shall have the right, but not the obligation, to bring suit      against such Third Party infringer of the Intellectual Property Rights      and/or the Trademark and to join ULURU as a party plaintiff, provided that      MEDA shall bear all the expenses of such suit. In such event, MEDA shall      not consent to the entry of any judgment or enter into any settlement with      respect to such an action or suit without the prior written consent of      ULURU (which consent shall not unreasonably be withheld) if such judgment      or settlement includes a finding or agreement that such Intellectual      Property Right and/or the Trademark is invalid or would enjoin or grant      other equitable relief againstULURU. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5.3.   | Each      Party shall cooperate (including, without limitation, by executing any      documents reasonably required to enable the other Party to initiate such      litigation, testifying when requested or providing relevant documents)      with the other Party in any suit for infringement of Intellectual Property      Rights and/or the Trademark brought by the other Party against a Third      Party in accordance with this Section and shall have the right to consult      with the other Party and to participate in and be represented by      independent counsel in such litigation at its own  expense. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5.4.   | Neither      Party shall be required pursuant to this Section 12.5 to undertake any      activities, including, without limitation, legal discovery at the request      of a Third Party except as may be required by lawful process of a court of      competent jurisdiction. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5.5.   | Neither      Party shall incur any liability to the other Party as a consequence of any      such litigation or any unfavorable decision resulting therefrom,      including, without limitation, any decision holding any of the patents      within the Intellectual Property Rights invalid or      unenforceable. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5.6.   | Any      recovery obtained by either Party as a result of any such proceeding      against a Third Party infringer shall be allocated as follows: (a) such      recovery shall first be used to reimburse each Party for all litigation      costs in connection with such litigation paid by that Party; and (b) the      Party bringing the action shall receive the remaining portion of such      recovery after payment of the amounts specified in clause    (a). |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.6.   | MEDA      Trademarks. |
|-------------------|-----------------------|

| 12.7.   | Publications. |
|-------------------|---------------|

| 12.7.1.   | The      Parties recognize that limited rights of review and/or comment exist for      certain Third Party publications, such as medical, academic and scientific      publications. Each Party agrees to provide the other Party with any such      proposed publication or presentation promptly upon its receipt. Each Party      may advise the other of any comments that it may have relating to such      proposed publication or presentation and do so within the applicable time      frame. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.7.2.   | During      the Term of this Agreement, unless otherwise prohibited by law, each Party      shall submit to the other Party for review and approval any proposed      publication or public presentation, especially including, without      limitation, academic, scientific and medical information, which contains      the non-disclosing Party’s Confidential Information or which disclose any      non-public information contained within the Intellectual Property Rights      or which makes any reference to the subject matter of this Agreement or      the Products. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.7.3.   | Written      copies of each such proposed publication or presentation required to be      submitted hereunder shall be submitted to the non-disclosing Party no      later than fifteen (15) days before its intended submission for      publication or presentation. The non-disclosing Party shall provide its      comments with respect to such publications and presentations within ten      (10) business days of its receipt of such written copy. The review period      may be extended for an additional thirty (30) days in the event the non-      disclosing Party can demonstrate reasonable need for such extension. By      mutual agreement of the Parties in writing, this period may be further      extended. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.7.4.   | The      Parties acknowledge that as publicly held corporations, the Parties may      not lawfully disclose in advance certain information to any party,      including, without limitation, the other Party. This may affect the      Parties’ ability to submit for review certain proposed publications and      public presentations. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.7.5.   | Regarding      their publications under this Section 12.7, MEDA and ULURU will each      comply with standard academic practice regarding authorship of scientific      publications and recognition of contribution of other parties in any      publication. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 13.   | NOTICES |
|-----------------|---------|

| 13.1.   | Ordinary      Notices. |
|-------------------|------------------------|

| 13.2.   | Extraordinary      Notices. |
|-------------------|-----------------------------|

| 13.2.1.   | Extraordinary      notices and communications (including, without limitation, notices of      termination, Force Majeure Event, material breach, change of address,      requests for disclosure of Confidential Information, claims or      indemnification) shall be in writing and shall be delivered by hand, sent      by facsimile or by overnight courier (and shall be deemed to have been      properly served to the addressee upon receipt of such written      communication) to the address set forth in Section 13.3 or such other      address as notified in writing by such Party to the other      Party. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.3.   | Addresses. |
|-------------------|------------|

----

| 14.   | GENERAL |
|-----------------|---------|

| 14.1.   | Governing      Law. |
|-------------------|---------------------|

| 14.2.   | Dispute Resolution /      Arbitration Proceedings. |
|-------------------|----------------------------------------------------|

| 14.2.1.   | If      one Party is of the opinion that the other Party has infringed any of its      Confidential Information under this Agreement, then this Party may      commence proceedings for infringement in any court of competent      jurisdiction to enforce the said Confidential Information, including      without limitation to apply injunctiverelief. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.2.2.   | All      disputes arising out of or in connection with this Agreement (other than      those which a Party has elected to submit to national courts under Section      14.2.1) shall first be attempted to be settled between the Parties on a      good faith basis. If the Parties are unable to resolve the dispute within      60 (sixty) days from the receipt by one Party of the other Party’s written      notice asking for such amicable settlement discussions, then such dispute      shall be finally settled by arbitration in accordance with the      International Chamber of Commerce (ICC) Rules of Arbitration by three      arbitrators, appointed in accordance with said rules. The place of      arbitration shall be Zurich, Switzerland. The proceedings shall be      conducted and all documentation shall be presented in    English. |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.3.   | Assignment. |
|-------------------|-------------|

----

| 14.4.   | Entire      Agreement. |
|-------------------|------------------------|

| 14.5.   | Severability. |
|-------------------|---------------|

| 14.6.   | Independent      Contractor. |
|-------------------|------------------------------|

| 14.7.   | No      Waiver. |
|-------------------|-----------------|

| 14.8.   | Counterparts. |
|-------------------|---------------|

| 14.9.   | Exhibits. |
|-------------------|-----------|

----

----

| Product                    | Substance | Presentation         |
|----------------------------|-----------|----------------------|
| 5%      amlexanox paste    | amlexanox | 3 g      tube        |
| OraDisc      A (amlexanox) | amlexanox | 2      mg (per disc) |

----

----

----

| TITLE                                                                                       | SERIALNO/PATENT      NO | ISSUED    | COUNTRY            |
|---------------------------------------------------------------------------------------------|-------------------------|-----------|--------------------|
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Austria            |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Belgium            |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Switzerland        |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Germany            |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Denmark            |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Spain              |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | France             |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Great      Britain |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Greece             |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Italy              |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Luxembourg         |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Monaco             |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Netherlands        |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Portugal           |
| Use      of Amlexanox for the Manufacture of a Medicament for Treating Aphthous      Ulcers | 972025240836852         | 4/22/1998 | Sweden             |

----

| Parameter                           | Specification                                                                                                |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------|
| Appearance                          | Homogenous      granular beige/tan colored paste free of lumps and foreign particles,      packaged in tubes |
| Amlexanox      Identification       | Positive                                                                                                     |
| Amlexanox      Assay                | 4.75%      - 5.25%                                                                                           |
| Benzyl      Alcohol Assay           | 2.25%      - 2.75%                                                                                           |
| AA-896      Content                 | < 0.005%                                                                                                  |
| Viscosity                           | 0.25      x 106      cps – 4.50 x 106      cps                                                         |
| Particle      Size (<30 μm) | 2 –      25 μm                                                                                    |
| Fill      Weight                    | 5.0      – 5.8 g                                                                                       |

| Microbial      Limits  |           |
|-----------------------------|----------------|
| Aerobic      Plate Count    | < 500 CFU/g |
| Yeast/Molds                 | < 100 CFU/g |
| Pseudomonas      species    | Absent         |
| S.      aureus              | Absent         |
| E.      coli                | Absent         |
| Salmonella      species     | Absent         |

----

| Parameter                                                                                                                   | Specification                                                                                                                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Appearance                                                                                                                  | Round,      1⁄2” diameter patch, red on one side and white on the other    side                                                                                                                                                                    |
| Amlexanox      Content                                                                                                      | 2.00±      0.10 mg                                                                                                                                                                                                                                     |
| Degradants:TotalAA-896Unidentified                                                                                          |   ≤      0.1% Amlexanox Content≤      0.1% Amlexanox Content≤      0.1% Amlexanox Content                                                                                                                                  |
| Content      Uniformity(d.u.      = dosage unit)                                                                            | 1.70      – 2.30 mg for at least 9 of 10 d.u. tested, no d.u. outside of 1.50 – 2.50      mg; RSD ≤6.0%OR1.70      – 2.30 mg for at least 27 of 30 d.u. tested, no d.u. outside of 1.50 –      2.50 mg; RSD ≤7.8%  |
| Dissolution                                                                                                                 | Q = 75% for Amlexanox      Released in 60 min.Acceptance      per USP<711> Unit Sample                                                                                                                                                                |
| Weight                                                                                                                      | 35      – 45 mg                                                                                                                                                                                                                                       |
| Microbial      Limits:Aerobic      CountAerobic      Spore CountFungiE.      coliP.      aeruginosaSalmonellaS.      aureus |  <10      CFU/patch<10      CFU/patch<10      CFU/patch<10      CFU/patchNegativeNegativeNegativeNegative                                                                                                                                  |

----

----

----

----

| ·   | France                                                100,000      Euros |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Germany                                                100,000      Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Italy                                      100,000      Euros |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | United      Kingdom                                                           100,000      Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Belgium                                                        25,000 Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Netherlands                                                             50,000      Euros |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Turkey                                                  50,000      Euros |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Spain*                                                75,000      Euros |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2 | In      the event that the Regulatory Authorities does not grant the Regulatory      Approval for OraDiscTM A, for whatever reason, in a country mentioned      above, ULURU shall pay back to MEDA 50 (fifty) % of the license      payment for the respective country. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.3 | For      the remaining countries of the Territory there are no license payments      applicable on the Effective Date. |
|-----|------------------------------------------------------------------------------------------------------------------------|

| 2.1 | Upon      Launch of Apthasol Paste (amlexanox) in the countries mentioned below,      MEDA will pay ULURU the following license  payments: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Germany                                                200,000      Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | United      Kingdom                                                           200,000      Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Belgium                                                        25,000 Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Netherlands                                                              25,000      Euros |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2 | For      the remaining countries of the Territory there are no license payments      applicable upon      Apthasol Paste. |
|-----|--------------------------------------------------------------------------------------------------------------------------------|

| 3.1 | Upon      Launch of OraDiscTM A in the countries mentioned below, MEDA will pay ULURU      the following license payments: |
|-----|---------------------------------------------------------------------------------------------------------------------------------|

| ·   | France                                                500,000      Euros |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Germany                                                300,000      Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Italy                                      500,000      Euros |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | United      Kingdom                                                           300,000      Euros |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Belgium                                                   50,000      Euros |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Netherlands                                                            75,000      Euros |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Turkey                                                 100,000      Euros |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | Spain*                                                325,000      Euros |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2 | For      the remaining countries of the Territory there are no license payments      applicable upon launch of OraDiscTM. |
|-----|--------------------------------------------------------------------------------------------------------------------------------|

| 4.) | License Payments No. 4      (Upon achievement of cumulated Net Sales in a calendar      year) |
|-----|-----------------------------------------------------------------------------------------------|

| 4.1 | Upon      the achievement of certain Net Sales of the Products within the countries      of the Territory in a calendar year, MEDA will pay ULURU the following      license payments, whereupon it is understood that these license payments      are to be one time payments: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | 250,000      Euros (two hundred fifty thousand) when cumulated Net Sales in a calendar      year is equal to or greater than 5,000,000 Euros (five      million) |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | 500,000      Euros (five hundred thousand) when cumulated Net Sales in a calendar year      is equal to or greater than 15,000,000 Euros (fifteen    million) |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | 750,000      Euros (seven hundred fifty thousand) when cumulated Net Sales in a      calendar year is equal to or greater than 25,000,000 Euros (twenty five      million) |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | 1.000,000      Euros (one million) when cumulated Net Sales in a calendar year is      equal to or greater than 40,000,000 Euros (forty  million) |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | Cumulative      Net Sales in the countries of the Territory will be converted from local      currency into Euros based on currency exchange rates published in the Wall      Street Journal. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Country             | Trademark |
|---------------------|-----------|
| Denmark             | AFTASOL   |
| Finland             | AFTASOL   |
| Norway              | AFTASOL   |
| Sweden              | AFTASOL   |
| United      Kingdom | Aphtheal  |
| United      Kingdom | Aftasol   |
| Netherlands         | Miraftil  |
| Luxembourg          | Miraftil  |
| Austria             | Aftasol   |
| Ireland             | Aphtheal  |
| Germany             | Miraphtil |

----